Oral treatment with laquinimod augments regulatory T-cells and brain-derived neurotrophic factor expression and reduces injury in the CNS of mice with experimental autoimmune encephalomyelitis-Reference-Cited by-同舟云学术

Oral treatment with laquinimod augments regulatory T-cells and brain-derived neurotrophic factor expression and reduces injury in the CNS of mice with experimental autoimmune encephalomyelitis

Published:2012-10 Issue:1-2 Volume:251 Page:14-24
ISSN:0165-5728
Container-title:Journal of Neuroimmunology
language:en
Short-container-title:Journal of Neuroimmunology

Author:

Aharoni Rina,Saada Ravit,Eilam Raya,Hayardeny Liat,Sela Michael,Arnon Ruth

Funder

Teva Pharmaceutical Industries (Israel)

Publisher

Elsevier BV

Subject

Clinical Neurology,Neurology,Immunology,Immunology and Allergy

Reference26 articles.

1. Linkage between immunomodulation neuroprotection and neurogenesis;Aharoni;Drug News Perspect.,2009

2. The immunomodulator glatiramer acetate augments the expression of neurotrophic factors in brains of experimental autoimmune encephalomyelitis mice;Aharoni;Proc. Natl. Acad. Sci. U. S. A.,2005

3. Neurogenesis and neuroprotection induced by peripheral immunomodulatory treatment of experimental autoimmune encephalomyelitis;Aharoni;J. Neurosci.,2005

4. Lower brain-derived neurotrophic factor in serum of relapsing remitting MS: reversal by glatiramer acetate;Azoulay;J. Neuroimmunol.,2005

5. New insights into cell responses involved in experimental autoimmune encephalomyelitis and multiple sclerosis;Behi;Immunol. Lett.,2005

Cited by 61 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Kynurenines and Inflammation: A Remarkable Axis for Multiple Sclerosis Treatment;Pharmaceuticals;2024-07-25

2. Neuroimmunomodulatory properties of laquinimod;Brain Disorders;2024-03

3. Laquinimod Inhibits Microglial Activation, Astrogliosis, BBB Damage, and Infarction and Improves Neurological Damage after Ischemic Stroke;ACS Chemical Neuroscience;2023-05-10

4. Neuroinflammation in Huntington’s disease: From animal models to clinical therapeutics;Frontiers in Immunology;2022-12-22

5. Recent advances in clinical trials targeting the kynurenine pathway;Pharmacology & Therapeutics;2022-08